International Journal of Medical Science and Public Health Research

Quality Of Life Assessment In Patients With Myelodysplastic Syndrome

Yunusova Zulkhumor Jumaboevna — 2025-10-15

Objective: To evaluate health-related quality of life (HRQoL) in patients with myelodysplastic syndrome (MDS).

Methods: A total of 234 patients with MDS, aged 18–72 years and originating from different regions of the republic, were enrolled between 2018 and 2025 during hospitalization at the 2nd Hematology Department of the Republican Specialized Scientific and Practical Medical Center of Hematology. Clinical examination, laboratory investigations, and assessment of HRQoL using the Short Form-36 (SF-36) questionnaire were performed. Data were analyzed using appropriate statistical methods.

Results: Analysis of SF-36 scores revealed a marked reduction in both the physical and mental health components among patients with MDS.

Conclusion: Patients with MDS experience substantially impaired quality of life, reflected in significant limitations across both physical and psychological domains.

A Comprehensive Review Of Ocular Manifestations In Rheumatoid Arthritis: From Pathophysiology To Clinical Management

Dr. Eleanor Vance — 2025-10-01

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that frequently presents with extra-articular manifestations. Ocular involvement is common and can range from mild discomfort to sight-threatening conditions. This review provides a comprehensive overview of the visual complaints and ocular manifestations in patients with RA.

Methods: A literature review was conducted using a systematic approach to identify relevant articles on the ocular manifestations of RA. The search included peer-reviewed articles, clinical trials, and case reports. The focus was on the pathophysiology, clinical presentation, diagnosis, and management of these conditions.

Results: The most common ocular manifestation of RA is keratoconjunctivitis sicca (dry eye syndrome). Other significant anterior segment complications include episcleritis, scleritis, and peripheral ulcerative keratitis. Posterior segment involvement, such as uveitis and retinal vasculitis, is less common but can be more severe. A critical aspect of management is monitoring for drug-induced toxicities, particularly hydroxychloroquine retinopathy, which can cause irreversible vision loss (1). The risk of QT interval prolongation with hydroxychloroquine use, especially with concomitant medications, also warrants consideration (2). Recent clinical trials have provided further insights into the implications of these ocular manifestations (3).

Conclusion: Ocular manifestations in RA are diverse and require a high index of suspicion for early diagnosis and treatment. A multidisciplinary approach involving rheumatologists and ophthalmologists is essential for optimal patient care. Regular ophthalmic screening is recommended for all RA patients, especially those on long-term hydroxychloroquine therapy, to prevent irreversible vision loss and improve quality of life.

Eﬀect Of Hyperosmolar 3,5% Nacl Solution On Cerebral Edema In Patients With Traumatic Brain Injury

Temur Malik Murotov — 2025-10-08

In the structure of injuries, traumatic brain injury is the most dramatic. TBI remains one of the most important public health problems. Background: To study the eﬀect of early administration of 3,5% HSS on systemic, central hemodynamics, hemostasis, ICP, CPP, efcacy and safety in isolated traumatic brain injury in an adult population. Material and methods: The study design was a retrospective - 16 patients and prospective 20-patient, single-center, randomized open clinical trial of 36 patients treated in intensive care unit (ICU) with isolated traumatic brain injury aged 18 to 88 years with depression of consciousness (4-12 Glasgow scale score), and abnormal head computed tomography fndings on admission. Daily data during 7 days after admission to the TBI included hourly measurements of ICP, recorded noninvasively using Complexmed 1.2, and if possible, by lumbar subarachnoid puncture with manometry in 9 patients, determination of serum sodium, pulse oximetry and measurements of daily diuresis, plasma osmolarity. Results: At 20-25 minutes after thebolus of 3,5% HSS injection, the ICP decreased (stage 2) below 20 mmHg, reaching an average of 19,7 mmHg, i.e. decreasing relative to the initial data by 26,3% (p<0,05). The maximum decrease of ICP was noted at the 3rd stage of the study (after 30 minutes), where, amounting to 18, 9 ± 0.73 mmHg, it was 29,3% (p<0,05) lower than the initial values. Conclusions: NaCl HSS can be used as early as possible in patients with traumatic brain injury and high risk of developing ICH.